RTK Group

RTK Group is a family office-backed biopharmaceutical advisory and investment fund focusing on early-stage companies developing emerging technologies. The firm targets disruptive innovations with significant potential to benefit patients, primarily in the biotech and pharmaceutical sectors. RTK Group's investment strategy centers on pre-seed funding rounds.

The firm's portfolio includes Unravel Biosciences, a company that has raised $1,650,000 to date. RTK Group's mission is to accelerate the development of promising technologies to improve patient lives. By offering both advisory services and investment capital, RTK Group aims to catalyze breakthrough innovations in the biopharmaceutical industry.